Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer.
Paiella S, Capurso G, Carrara S, Secchettin E, Casciani F, Frigerio I, Zerbi A, Archibugi L, Bonifacio C, Malleo G, Cavestro GM, Barile M, Larghi A, Assisi D, Fantin A, Milanetto AC, Fabbri C, Casadei R, Donato G, Sassatelli R, De Marchi G, Di Matteo FM, Arcangeli V, Panzuto F, Puzzono M, Dal Buono A, Pezzilli R, Salvia R, Rizzatti G, Casadio M, Franco M, Butturini G, Pasquali C, Coluccio C, Ricci C, Cicchese N, Sereni G, de Pretis N, Stigliano S, Rudnas B, Marasco M, Lionetto G, Arcidiacono PG, Terrin M, Crovetto A, Mannucci A, Laghi L, Bassi C, Falconi M. Paiella S, et al. Among authors: rudnas b. Am J Gastroenterol. 2024 Apr 1;119(4):739-747. doi: 10.14309/ajg.0000000000002546. Epub 2023 Oct 3. Am J Gastroenterol. 2024. PMID: 37787643
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
Reni M, Giommoni E, Bergamo F, Milella M, Cavanna L, Di Marco MC, Spada M, Cordio S, Aprile G, Cardellino GG, Maiello E, Bernardini I, Ghidini M, Bozzarelli S, Macchini M, Orsi G, De Simone I, Rulli E, Porcu L, Torri V, Pinto C; GARIBALDI Study Group. Reni M, et al. ESMO Open. 2023 Feb;8(1):100777. doi: 10.1016/j.esmoop.2022.100777. Epub 2023 Feb 1. ESMO Open. 2023. PMID: 36731325 Free PMC article.
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study.
Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P, Foschi FG, Tamburini E, Vivaldi C, Rizzato MD, Ielasi L, Canale M, Conti F, Rudnas B, Fornaro L, Silvestris N, Silletta M, Cardellino GG, Lonardi S, Fornari F, Orsi G, Rovesti G, Zagonel V, Cascinu S, Scartozzi M. Casadei-Gardini A, et al. Among authors: rudnas b. Clin Cancer Res. 2020 Sep 1;26(17):4485-4493. doi: 10.1158/1078-0432.CCR-19-3897. Epub 2020 May 5. Clin Cancer Res. 2020. PMID: 32371540
Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials.
Tamburini E, Tassinari D, Ramundo M, De Stefano A, Viola MG, Romano C, Elia MT, Zanaletti N, Rudnas B, Casadei-Gardini A, Delrio P, Toma I, Granata V, Petrucelli L, Avallone A. Tamburini E, et al. Among authors: rudnas b. Crit Rev Oncol Hematol. 2022 Apr;172:103627. doi: 10.1016/j.critrevonc.2022.103627. Epub 2022 Feb 22. Crit Rev Oncol Hematol. 2022. PMID: 35202817 Review.
Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial.
Passardi A, Rapposelli IG, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Avanzolini A, Cavaliere D, Rudnas B, Valgiusti M, Barone D, Ferroni F, Frassineti GL, Romeo A. Passardi A, et al. Among authors: rudnas b. Ther Adv Med Oncol. 2020 Dec 8;12:1758835920977139. doi: 10.1177/1758835920977139. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33343722 Free PMC article.
How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment Tool.
Fabbri F, Gentili G, Serra P, Vertogen B, Andreis D, Dall'Agata M, Fabbri G, Gallà V, Massa I, Montanari E, Monti M, Pagan F, Piancastelli A, Ragazzini A, Rudnas B, Testoni S, Valmorri L, Zingaretti C, Zumaglini F, Nanni O. Fabbri F, et al. Among authors: rudnas b. JCO Oncol Pract. 2021 Jan;17(1):e68-e76. doi: 10.1200/JOP.19.00386. Epub 2020 Sep 16. JCO Oncol Pract. 2021. PMID: 32936710
Maintenance based Bevacizumab versus complete stop or continuous therapy after induction therapy in first line treatment of stage IV colorectal cancer: A meta-analysis of randomized clinical trials.
Tamburini E, Rudnas B, Santelmo C, Drudi F, Gianni L, Nicoletti SV, Ridolfi C, Tassinari D. Tamburini E, et al. Among authors: rudnas b. Crit Rev Oncol Hematol. 2016 Aug;104:115-23. doi: 10.1016/j.critrevonc.2016.05.016. Epub 2016 Jun 9. Crit Rev Oncol Hematol. 2016. PMID: 27338848 Review.
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.
Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, Brunetti O, Rudnas B, Pisconti S, Valgiusti M, Marisi G, Foschi FG, Ercolani G, Tassinari D, Cascinu S, Frassineti GL. Casadei Gardini A, et al. Among authors: rudnas b. Sci Rep. 2017 Feb 13;7:42499. doi: 10.1038/srep42499. Sci Rep. 2017. PMID: 28211921 Free PMC article.
21 results